Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG-PET/CT and Cetuximab in Metastatic SCCHN
NCT00671437Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2008
- Primary completion
- Dec 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Washington University School of Medicine. Primary endpoint: Metabolic Response of Target Lesions Assessed as the Change in Standardized Uptake Values (SUV) Max on FDG-PET/CT at 8 weeks. Started Jun 2008; status: completed.
02
Drugs
cetuximab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00671437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671437.